Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Service d’hématologie clinique CHU de Nice

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article provides an overview of the CHU de Nice's clinical hematology service, detailing its management structure, collaborations, patient studies, and pipeline of treatments. It highlights ongoing studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, as well as the company's commitment to scientific research and patient care.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 44 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by CHU de Nice?

CHU de Nice sponsors studies such as TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is Emavusertib?

Emavusertib, also known as CA-4948, is part of the treatment pipeline at CHU de Nice.

What collaborations does CHU de Nice have?

CHU de Nice engages in partner collaborations and scientific research collaborations.

How can I find financial information about CHU de Nice?

Financial information, including SEC filings and annual reports, is available on their website.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare CHU de Nice clinical hematology TakeAim studies Emavusertib Fimepinostat
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →